Goodbye Middle Class: 51 Percent Of All American Workers Make Less Than 30,000 Dollars A Year

http://endoftheamericandream.com/archives/goodbye-middle-class-51-percent-of-all-american-workers-make-less-than-30000-dollars-a-year

Thanks. Backfired

Not in the money....lol. Unless confirm QE in the place, market will behave like this.

$LPCN FDA Approval on Track for 2016…

https://finance.yahoo.com/news/lpcn-files-nda-lpcn-1021-200000373.html

$LPCN FDA Approval on Track for 2016…

https://finance.yahoo.com/news/lpcn-files-nda-lpcn-1021-200000373.html

$LPCN Updated corporate presentation

http://files.shareholder.com/downloads/AMDA-2BVSIV/865335907x0x854540/02A0C183-90F8-4111-9DFD-53EF25A00674/LPCN_Presentation_October_FINAL.pdf


Highlights

First oral testosterone replacement option
– Targeting ~ $2.0 Billion TRT market
– NDA submitted August 2015
– Differentiated from existing products
Orphan designated oral alternative for the prevention of preterm birth
– Avoids painful injections of the only FDA approved intra-muscular drug
– Multi-dose PK study expected to start 4Q 2015
Strong Balance Sheet
– Over $53M in Cash as of June 30th – Sufficient to last past LPCN 1021 anticipated
PDUFA date
– No Debt

$LPCN Updated corporate presentation

http://files.shareholder.com/downloads/AMDA-2BVSIV/865335907x0x854540/02A0C183-90F8-4111-9DFD-53EF25A00674/LPCN_Presentation_October_FINAL.pdf


Highlights

First oral testosterone replacement option
– Targeting ~ $2.0 Billion TRT market
– NDA submitted August 2015
– Differentiated from existing products
Orphan designated oral alternative for the prevention of preterm birth
– Avoids painful injections of the only FDA approved intra-muscular drug
– Multi-dose PK study expected to start 4Q 2015
Strong Balance Sheet
– Over $53M in Cash as of June 30th – Sufficient to last past LPCN 1021 anticipated
PDUFA date
– No Debt

The majority of societies prevailing view due to Big Pharma's, disinformation. lies, threats, cover ups, payoffs, bribes, brainwashing results

You are missing point here. Stay away from making cheap comments unless you have in-depth knowledge on the subject

Valeant big pharma ceo: We're in the business of shareholder profit, not helping the sick.....

http://www.healthnutnews.com/valeant-pharmaceuticals-ceo-were-in-business-of-shareholder-profit-not-helping-the-sick/

very honest confession

$LPCN Product Pipeline Review – 2015

http://www.medgadget.com/2015/10/lipocine-inc-product-pipeline-review-2015.html

Not sure how market will react NASDAQ:RLYP FDA approval date Oct 21, 2015

http://www.insidertradingreport.org/relypsa-inc-nasdaqrlyp-analyst-price-target/6119296/

'm in

Not sure how market will react NASDAQ:RLYP FDA approval date Oct 21, 2015

http://www.insidertradingreport.org/relypsa-inc-nasdaqrlyp-analyst-price-target/6119296/

$LPCN expecting be a good week...PDUFA might be announced

$LPCN expecting be a good week...PDUFA might be announced

JOHN HIGUCHI INSIDER BUYING FOR 5,000 SHARES OF LIPOCINE INC (NASDAQ:LPCN)

http://www.financialbio.com/insider-trades/john-higuchi-insider-buying-for-5000-shares-of-lipocine-inc-nasdaqlpcn-11882.html

JOHN HIGUCHI INSIDER BUYING FOR 5,000 SHARES OF LIPOCINE INC (NASDAQ:LPCN)

http://www.financialbio.com/insider-trades/john-higuchi-insider-buying-for-5000-shares-of-lipocine-inc-nasdaqlpcn-11882.html

Did you know that nearly 20 percent of corporate crime is being committed by companies that make products for your health?

http://theantimedia.org/the-pharmaceutical-industry-is-an-organized-drug-cartel/

Scottrade hacked, customer data stolen

http://money.cnn.com/2015/10/02/technology/scottrrade-hack/index.html

$LPCN Files Form 4 Insider Buying

http://www.insidertradingreport.org/lipocine-inc-lpcn-files-form-4-insider-buying-mahesh-v-patel-buys-4000-shares/6115640/

Lipocine Inc. director just picked up 5,000 shares

http://www.conferencecalltranscripts.org/4/summary/?id=2061620

Nuvo Research Spin-Out Should Unlock Value For Investors

http://seekingalpha.com/article/3546896-nuvo-research-spin-out-should-unlock-value-for-investors?auth_param=i5mo:1b0sp0g:2c65eae6880230f433fd64a416f9e950

Nuvo Research Spin-Out Should Unlock Value For Investors

http://seekingalpha.com/article/3546896-nuvo-research-spin-out-should-unlock-value-for-investors?auth_param=i5mo:1b0sp0g:2c65eae6880230f433fd64a416f9e950

Swing play for today

Company Update (NASDAQ:XOMA): XOMA Corp Announces Development and Commercialization Agreement for First-in-Class Anti-TGF-beta Antibody Program in Immuno-Oncology

http://www.smarteranalyst.com/2015/10/01/company-update-nasdaqxoma-xoma-corp-announces-development-and-commercialization-agreement-for-first-in-class-anti-tgf-beta-antibody-program-in-immuno-oncology/

Opexa Therapeutics (OPXA) is Reiterated by Maxim Group to Buy, Raises Price Target to $18

http://www.moneyflowindex.org/opexa-therapeutics-opxa-is-reiterated-by-maxim-group-to-buy-raises-price-target-to-18/3139557/

Opexa Therapeutics (OPXA) is Reiterated by Maxim Group to Buy, Raises Price Target to $18

http://www.moneyflowindex.org/opexa-therapeutics-opxa-is-reiterated-by-maxim-group-to-buy-raises-price-target-to-18/3139557/

$LPCN the song remains the same-good company about to launch good product. Don't know why it keeps dropping?

NASDAQ:NKTR - no matter market is bull or bear, a safe play

http://www.americantradejournal.com/nektar-therapeutics-nasdaqnktr-analyst-rating-update/696179/

Keep an eye on OPXA ...

$5 end of today....my guess

Keep an eye on OPXA ...

$5 end of today....my guess

Nuvo Research: Two Companies For Less Than The Price Of One

http://seekingalpha.com/article/3542396-nuvo-research-two-companies-for-less-than-the-price-of-one?auth_param=i5mo:1b0no0b:f0e46c2d7d080c1a19560e57f61e7aef

Nuvo Research: Two Companies For Less Than The Price Of One

http://seekingalpha.com/article/3542396-nuvo-research-two-companies-for-less-than-the-price-of-one?auth_param=i5mo:1b0no0b:f0e46c2d7d080c1a19560e57f61e7aef

Will Valeant Pharmaceuticals (VRX) Stock Continue to Rebound?

http://www.thestreet.com/story/13304926/1/will-valeant-pharmaceuticals-vrx-stock-continue-to-rebound.html

Will Valeant Pharmaceuticals (VRX) Stock Continue to Rebound?

http://www.thestreet.com/story/13304926/1/will-valeant-pharmaceuticals-vrx-stock-continue-to-rebound.html

big move on the way

Will Valeant Pharmaceuticals (VRX) Stock Continue to Rebound?

http://www.thestreet.com/story/13304926/1/will-valeant-pharmaceuticals-vrx-stock-continue-to-rebound.html

big move on the way

HC Wainwright Reiterates Buy Rating for IntelGenx Technologies Corp. (IGXT)

http://www.lulegacy.com/2015/09/23/hc-wainwright-reiterates-buy-rating-for-intelgenx-technologies-corp-igxt/619533/

$lPCN TO Present at Ladenburg Thalmann 2015 Healthcare Conference TOMORROW

http://globenewswire.com/news-release/2015/09/22/770048/10150032/en/Lipocine-to-Present-at-Ladenburg-Thalmann-2015-Healthcare-Conference.html?parent=771448

$lPCN TO Present at Ladenburg Thalmann 2015 Healthcare Conference TOMORROW
http://globenewswire.com/news-release/2015/09/22/770048/10150032/en/Lipocine-to-Present-at-Ladenburg-Thalmann-2015-Healthcare-Conference.html?parent=771448

$LPCN Announces First Subject Dosed in Multi-Dose PK Study for Its Oral Product Candidate for the Prevention of Pre-Term Birth

http://globenewswire.com/news-release/2015/09/28/771448/10150700/en/Lipocine-Announces-First-Subject-Dosed-in-Multi-Dose-PK-Study-for-Its-Oral-Product-Candidate-for-the-Prevention-of-Pre-Term-Birth.html#sthash.ewjS3Lkd.dpuf

$LPCN Announces First Subject Dosed in Multi-Dose PK Study for Its Oral Product Candidate for the Prevention of Pre-Term Birth

http://globenewswire.com/news-release/2015/09/28/771448/10150700/en/Lipocine-Announces-First-Subject-Dosed-in-Multi-Dose-PK-Study-for-Its-Oral-Product-Candidate-for-the-Prevention-of-Pre-Term-Birth.html#sthash.ewjS3Lkd.dpuf

Chart Comparing Global Drug Prices

http://thefreethoughtproject.com/chart-compares-drug-prices-world-exposes-govt-creates-windfall-big-pharma/

Passed the test of 50 day MA

OTC: NRIFF TSX: NRI ... Excellent DD

http://www.stockhouse.com/companies/bullboard/t.nri/nuvo-research-inc?postid=24133802